Table 3.
Comparison of baseline characteristics grouped by SII, NLR, and LMR.
| Parameter | SII | NLR | LMR | ||||||
|---|---|---|---|---|---|---|---|---|---|
| <600 | ≥600 | p-value | <2.5 | ≥2.5 | p-value | <4.7 | ≥4.7 | p-value | |
| N = 72 | N = 70 | N = 67 | N = 75 | N = 81 | N = 61 | ||||
| Mean age (years) | 64.22 ± 9.64 | 61.87 ± 11.60 | 0.191 | 63.69 ± 10.28 | 62.51 ± 11.06 | 0.513 | 63.15 ± 11.09 | 62.95 ± 10.20 | 0.914 |
| Sex (male) | 29 (40.3%) | 31 (44.3%) | 0.629 | 23 (34.3%) | 37 (49.3%) | 0.071 | 39 (48.1%) | 21 (34.4%) | 0.101 |
| Median Alb (IQR) (g/L) | 42 (39–45) | 39 (35–42) | 0.001 | 42 (38–45) | 40 (36–42) | 0.007 | 39 (36–43) | 42 (39–45) | 0.003 |
| Median Tbil (IQR) (μmol/L) | 11.70 (10.05–17.80) | 15.25 (9.55–27.35) | 0.070 | 11.40 (10.00–16.90) | 15.20 (9.60–25.20) | 0.052 | 14.70 (9.50–25.80) | 11.40 (10.05–16.65) | 0.080 |
| Median NLR (IQR) | 1.80 (1.45–2.33) | 4.04 (2.98–5.20) | <0.001 | 1.72 (1.44–2.16) | 3.86 (2.94–5.17) | <0.001 | 3.63 (2.72–4.97) | 1.70 (1.43–2.14) | <0.001 |
| Median LMR (IQR) | 5.51 (4.26–6.47) | 3.16 (2.30–4.06) | <0.001 | 5.83 (4.97–6.63) | 3.17 (2.26–3.97) | <0.001 | 3.10 (2.24–3.87) | 5.96 (5.36–7.28) | <0.001 |
| Median SII (IQR) | 375.5 (277.0–471.7) | 1,092.0 (782.5–1,422.1) | <0.001 | 371.0 (273.3–473.5) | 1,041.1 (650.2–1,385.1) | <0.001 | 956.1 (595.4–1,337.8) | 374.5 (271.0–489.5) | <0.001 |
| Median CA 19-9 (IQR) (U/ml) | 22.8 (10.0–169.7) | 100.3 (16.5–271.2) | 0.009 | 21.7 (10.7–125.1) | 106.0 (14.6–298.7) | 0.007 | 98.1 (16.7–292.3) | 21.4 (9.7–1,137.6) | 0.003 |
| LNI | 24 (33.3%) | 40 (57.1%) | 0.004 | 20 (29.9%) | 44 (58.7%) | 0.001 | 48 (59.3%) | 16 (26.2%) | <0.001 |
| R0 resection | 53 (73.6%) | 35 (50.0%) | 0.004 | 52 (77.6%) | 36 (48.0%) | <0.001 | 38 (46.9%) | 50 (82.0%) | <0.001 |
| AJCC TNM stage | 0.002 | 0.001 | <0.001 | ||||||
| 0 | 4 (5.6%) | 1 (1.4%) | 4 (6.0%) | 1 (1.3%) | 1 (1.2%) | 4 (6.6%) | |||
| I | 10 (13.9%) | 1 (1.4%) | 9 (13.4%) | 2 (2.7%) | 2 (2.5%) | 9 (14.8%) | |||
| IIA | 7 (9.7%) | 5 (7.1%) | 7 (10.4%) | 5 (6.7%) | 4 (4.9%) | 8 (13.1%) | |||
| IIB | 1 (1.4%) | 0 (0.0%) | 1 (1.5%) | 0 (0.0%) | 0 (0.0%) | 1 (1.6%) | |||
| IIIA | 26 (36.1%) | 18 (25.7%) | 26 (38.8%) | 18 (24.0%) | 22 (27.2%) | 22 (36.1%) | |||
| IIIB | 16 (22.2%) | 26 (37.1%) | 14 (20.9%) | 28 (37.7%) | 29 (35.8%) | 13 (21.3%) | |||
| IVA | 1 (1.4%) | 8 (11.4%) | 1 (1.5%) | 8 (10.7%) | 8 (9.9%) | 1 (1.6%) | |||
| IVB | 7 (9.7%) | 11 (15.7%) | 5 (7.5%) | 13 (17.3%) | 15 (18.5%) | 3 (4.9%) | |||
| Median OS (months) | 34 | 11 | <0.001 | 37 | 12 | <0.001 | 13 | 40 | <0.001 |
Alb, albumin; Tbil, total bilirubin; NLR, neutrophil-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; SII, systemic immune-inflammation index; CA, carbohydrate antigen; LNI, lymph node invasion; AJCC, American Joint Committee on Cancer; OS, overall survival. The bold values represent that P value is less than 0.05.